{'fraction_non_alphanumeric': 0.05125628140703518, 'fraction_numerical': 0.05628140703517588, 'mean_word_length': 4.691428571428571, 'pattern_counts': {'":': 0, '<': 2, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Neuroprotective effects of a novel AMPA receptor antagonist, YM872

QUINOXALINEDIONES such as NBQX are neuroprotective in most models of cerebral ischemia but their poor solubility results in nephrotoxicity limiting their clinical utility. We have investigated the neuroprotective effects of a water soluble AMPA receptor antagonist, YM872, using two in vitro models. The viability of cortical cultures exposed to 400 μM AMPA for 15 min (16.4 ± 2.6%; n = 10) was significantly (p < 0.05) increased (84.7 ± 4.6%; n = 6) with YM872 (10 μM) in a concentration-dependent manner. Evoked post-synaptic response amplitudes in oxygen-glucose deprived hippocampal slices treated with 10 μM YM872 (3.5 ± 0.3 mV; n = 27) were significantly different from untreated deprived slices (0.3 ± 0.1 mV; n = 31, p < 0.05) and the CA1 neurons appeared viable using a confocal live/dead fluorescence assay with confocal microscopy. The neuroprotection seen with YM872 in vitro warrants further investigation in vivo.